Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Esai"

39 News Found

Govt. exhorts doctors to prescribe generic gedicines
Policy | July 31, 2023

Govt. exhorts doctors to prescribe generic gedicines

More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices


Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
News | July 04, 2023

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models


Ayush Minister inaugurates first Chintan Shivir
News | March 01, 2023

Ayush Minister inaugurates first Chintan Shivir

Sonowal exhorted young researchers and scientist to work on evidence based scientific research


No link between the use of ranitidine and cancer risk, claims Nature
News | February 24, 2023

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.


TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma
News | December 07, 2022

TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma

TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022


Aether Industries Q4 FY22 revenue up 26.8%; Profit up 13.8%
News | June 18, 2022

Aether Industries Q4 FY22 revenue up 26.8%; Profit up 13.8%

Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21


Aadi Bioscience announces collaborations with next generation sequencing leaders
Biotech | May 09, 2022

Aadi Bioscience announces collaborations with next generation sequencing leaders

The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


First patients ‘filter free’ after laser-assisted Inferior Vena Cava (IVC) filter removal
Public Health | April 22, 2022

First patients ‘filter free’ after laser-assisted Inferior Vena Cava (IVC) filter removal

The first use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter